hydroxychloroquine has been researched along with Glioma in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Excerpt | Relevance | Reference |
---|---|---|
" The bioavailability of IBR was largely improved, and enhanced sensitivity of glioma to IBR was achieved due to inhibition effect of HCQ on IBR-induced pro-survival autophagy." | 5.91 | Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. ( Du, Y; Gao, H; Lei, L; Li, Y; Tong, F; Wang, X; Xia, X; Yang, Z, 2023) |
" Recent studies showed that hydroxychloroquine can inhibit the latter step of autophagy and therefore enhance the anti-glioma efficiency of ZD6474, a tyrosine kinase inhibitor." | 3.88 | Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity. ( Chen, X; He, Q; Li, H; Li, M; Liu, Y; Long, Y; Lu, L; Qiu, Y; Tang, J; Wang, X; Yu, Q; Zhang, Z, 2018) |
" The bioavailability of IBR was largely improved, and enhanced sensitivity of glioma to IBR was achieved due to inhibition effect of HCQ on IBR-induced pro-survival autophagy." | 1.91 | Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. ( Du, Y; Gao, H; Lei, L; Li, Y; Tong, F; Wang, X; Xia, X; Yang, Z, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Yang, Z | 3 |
Du, Y | 3 |
Lei, L | 3 |
Xia, X | 3 |
Wang, X | 4 |
Tong, F | 3 |
Li, Y | 3 |
Gao, H | 4 |
Ruan, S | 1 |
Xie, R | 1 |
Qin, L | 1 |
Yu, M | 1 |
Xiao, W | 1 |
Hu, C | 1 |
Yu, W | 1 |
Qian, Z | 1 |
Ouyang, L | 1 |
He, Q | 2 |
Qiu, Y | 1 |
Yu, Q | 1 |
Li, H | 1 |
Chen, X | 1 |
Li, M | 1 |
Long, Y | 1 |
Liu, Y | 1 |
Lu, L | 1 |
Tang, J | 1 |
Zhang, Z | 1 |
3 other studies available for hydroxychloroquine and Glioma
Article | Year |
---|---|
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Topics: Animals; Cell Line, Tumor; Glioma; Humans; Hydroxychloroquine; Mice; Nanoparticles; Serum Albumin, H | 2023 |
Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment.
Topics: Analgesics; Animals; Antibodies; Autophagy; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; Dimeri | 2019 |
Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.
Topics: Animals; Antineoplastic Agents; Autophagy; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; End | 2018 |